Synthesis of Tolmetin Hydrazide-Hydrazones and Discovery of a Potent Apoptosis Inducer in Colon Cancer Cells

Archiv der Pharmazie

Volumn 348, Issue 10, 2015, Pages 730-742

  Küçükgüzel, Ş Güniz ^a   Koç, Derya ^a   Çikla Süzgün, Pelin ^a   Özsavci, Derya ^a   Bingöl Özakpinar, Özlem ^a   Mega Tiber, P D L D A L ^a   Orun, Oya ^a   Erzincan, P D L D A L ^a   Saʇ Erdem, Safiye ^a   Şahin, Fikrettin ^b  

^a MARMARA UNIVERSITY   (Turkey)

^b YEDITEPE UNIVERSITY   (Turkey)

Author keywords

Apoptosis; Caspase 3; Colon cancer; Hydrazide hydrazone; Tolmetin

Indexed keywords

2 [1 METHYL 5 (4 METHYLBENZOYL) 1H PYRROL 2 YL] ACETOHYDRAZIDE; 2 [1 METHYL 5 (4 METHYLBENZOYL) 1H PYRROL 2 YL] N' [(4 NITROPHENYL)METHYLIDENE]ACETOHYDRAZIDE; 2 [1 METHYL 5 (4 METHYLBENZOYL) 1H PYRROL 2 YL] N' [3 PHENOXYPHENYL METHYLIDENE]ACETOHYDRAZIDE; 2 [1 METHYL 5 (4 METHYLBENZOYL) 1H PYRROL 2 YL] N' [PHENYLMETHYLIDENE]ACETOHYDRAZIDE; 2 [1 METHYL 5 (4 METHYLBENZOYL) 1H PYRROL 2 YL] N' [PYRIDIN 3 YL METHYLIDENE]ACETOHYDRAZIDE; 2 [1 METHYL 5 (4 METHYLBENZOYL) 1H PYRROL 2 YL]ACETIC ACID; ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 8; CASPASE 9; CYCLOOXYGENASE 2; HYDRAZIDE DERIVATIVE; HYDRAZONE DERIVATIVE; LIPOCORTIN 5; METHYL 2 [1 METHYL 5 (4 METHYLBENZOYL) 1H PYRROL 2 YL]ACETATE; N' [(2 FLUOROPHENYL)METHYLIDENE] 2 [1 METHYL 5 (4 METHYLBENZOYL) 1H PYRROL 2 YL]ACETOHYDRAZIDE; N' [(2,4 DICHLOROPHENYL)METHYLIDENE] 2 [1 METHYL 5 (4 METHYLBENZOYL) 1H PYRROL 2 YL]ACETOHYDRAZIDE; N' [(2,6 DICHLOROPHENYL)METHYLIDENE] 2 [1 METHYL 5 (4 METHYLBENZOYL) 1H PYRROL 2 YL]ACETOHYDRAZIDE; N' [(4 BROMOPHENYL)METHYLIDENE] 2 [1 METHYL 5 (4 METHYLBENZOYL) 1H PYRROL 2 YL]ACETOHYDRAZIDE; N' [(4 CHLOROPHENYL)METHYLIDENE] 2 [1 METHYL 5 (4 METHYLBENZOYL) 1H PYRROL 2 YL]ACETOHYDRAZIDE; N' [(4 FLUOROPHENYL)METHYLIDENE] 2 [1 METHYL 5 (4 METHYLBENZOYL) 1H PYRROL 2 YL]ACETOHYDRAZIDE; N' [(4 METHOXYPHENYL)METHYLIDENE] 2 [1 METHYL 5 (4 METHYLBENZOYL) 1H PYRROL 2 YL]ACETOHYDRAZIDE; N' [FURAN 2 YL METHYLIDENE] 2 [1 METHYL 5 (4 METHYLBENZOYL) 1H PYRROL 2 YL]ACETOHYDRAZIDE; TOLMETIN; UNCLASSIFIED DRUG; CASP8 PROTEIN, HUMAN; CASP9 PROTEIN, HUMAN; CYCLOOXYGENASE 1; PROSTAGLANDIN SYNTHASE INHIBITOR; PTGS1 PROTEIN, HUMAN;

ANALYTIC METHOD; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL POPULATION; CELL VIABILITY; COLON CANCER; COLORIMETRY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG STRUCTURE; DRUG SYNTHESIS; ELEMENT ANALYSIS; EMBRYO; ENZYME ACTIVATION; ENZYME ACTIVE SITE; FIBROBLAST; HCT116 CELL LINE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HT 29 CELL LINE; HUMAN; HUMAN CELL; HYDROGEN BOND; IC50; IN VITRO STUDY; INFRARED SPECTROSCOPY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MITOCHONDRIAL MEMBRANE POTENTIAL; MOLECULAR DOCKING; MOUSE; MTT ASSAY; NONHUMAN; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; THIN LAYER CHROMATOGRAPHY; ULTRAVIOLET SPECTROSCOPY; ANALOGS AND DERIVATIVES; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; COLONIC NEOPLASMS; DOSE RESPONSE; DRUG DESIGN; DRUG EFFECTS; ENZYMOLOGY; HCT 116 CELL LINE; HT-29 CELL LINE; MCF-7 CELL LINE; METABOLISM; PATHOLOGY; PROTEIN CONFORMATION; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 8; CASPASE 9; CELL PROLIFERATION; CELL SURVIVAL; COLONIC NEOPLASMS; CYCLOOXYGENASE 1; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; ENZYME ACTIVATION; HCT116 CELLS; HT29 CELLS; HUMANS; HYDRAZONES; MCF-7 CELLS; MOLECULAR DOCKING SIMULATION; PROTEIN CONFORMATION; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; TOLMETIN;

EID: 84942980621     PISSN: 03656233     EISSN: 15214184     Source Type: Journal    
DOI: 10.1002/ardp.201500178     Document Type: Article

References (52)

1. D. Beck, P. Roberts, J. Rombeau, M. Stamos, S. Wexner, Colorectal cancer: epidemiology, etiology, and molecular basis, in The ASCRS Manual of Colon and Rectal Surgery (Eds.:, S. D. Wexner, M. J. Stamos, J. Rombeau, P. L. Roberts, D. E. Beck,), Springer, New York 2009, pp. 463-484.
2. J. R. Vane, R. M. Botting, Scand. J. Rheumatol. 1996, 25, 9-21.
3. G. A. Kune, S. Kune, L. F. Watson, Cancer. Res. 1988, 48 (15), 4399-4404.
4. M. J. Thun, M. M. Namboodiri, C. W. Heath, N. Engl. J. Med. 1991, 325 (23), 1593-1596.
5. E. Giovannucci, E. B. Rimm, M. J. Stampfer, G. A. Colditz, A. Ascherio, W. C. Willett, Ann. Intern. Med. 1994, 121 (4), 241-246.
6. D. Wang, R. N. DuBois, Oncogene 2009, 29 (6), 781-788.
7. R. E. Harris, Inflammopharmacology 2009, 17 (2), 55-67.
8. Z. Khan, N. Khan, R. P. Tiwari, N. K. Sah, G. Prasad, P. S. Bisen, Curr. Drug. Targets. 2011, 12 (7), 1082-1093.
9. S. Grösch, T. J. Maier, S. Schiffmann, G. Geisslinger, J. Natl. Cancer Inst. 2006, 98 (11), 736-747.
10. R. Narayanan, H. N. Kim, N. K. Narayanan, D. Nargi, B. Narayanan, Int. J. Oncol. 2012, 40 (1), 13-20.
11. T. O. Ishikawa, H. R. Herschman, Carcinogenesis 2010, 31 (4), 729-736.
12. P. Çikla, D. Özsavci, Ö. Bingöl-Özakpinar, A. Sener, Ö. Cevik, S. Özbaş-Turan, J. Akbuʇa, F. Sahin, Ş. G. Küçükgüzel, Arch. Pharm. 2013, 346 (5), 367-379.
13. Ş. G. Küçükgüzel, I. Coşkun, S. Aydin, G. Aktay, Ş. Gürsoy, Ö. Çevik, Ö. Bingöl-Özakpinar, D. Özsavci, A. Şener, N. Kaushik-Basu, A. Basu, T. T. Talele, Molecules 2013, 18 (3), 3595-3614.
14. S. Aydin, N. Kaushik-Basu, P. Arora, A. Basu, D. B. Nichols, T. T. Talele, M. Akkurt, I. Çelik, O. Büyükgüngör, Ş. G. Küçükgüzel, Marmara Pharm. J. 2013, 1 (17), 26-34.
15. P. Çikla, E. Tatar, I. Küçükgüzel, F. Şahin, D. Yurdakul, A. Basu, R. Krishnan, D. B. Nichols, N. Kaushik-Basu, Ş. G. Küçükgüzel, Med. Chem Res. 2013, 22, 5685-5699.
16. S. Aydin, N. Kaushik-Basu, S. Özbaş-Turan, J. Akbuʇa, P. Mega Tiber, O. Orun, K. R. Gurukumar, A. Basu, Ş. G. Küçükgüzel, Lett. Drug Des. Discov. 2014, 11 (2), 121-131.
17. C. P. Duffy, C. J. Elliott, R. A. O'Connor, M. M. Heenan, S. Coyle, I. M. Cleary, K. Kavanagh, S. Verhaegen, C. M. O'Loughlin, R. NicAmhlaoibh, M. Clynes, Eur. J. Cancer 1998, 34 (8), 1250-1259.
18. D. Lu, H. B. Cottam, M. Corr, D. A. Carson, Proc. Natl. Acad. Sci. USA 2005, 102 (51), 18567-18571.
19. S. Rollas, Ş. G. Küçükgüzel, Molecules 2007, 12, 1910-1939.
20. Ş. G. Küçükgüzel, E. E. Oruç, S. Rollas, F. Şahin, A. Özbek, Eur. J. Med. Chem. 2002, 37 (3), 197-206.
21. Ş. G. Küçükgüzel, A. Mazi, F. Sahin, S. Öztürk, J. Stables, Eur. J. Med. Chem. 2003, 38, 1005-1013.
22. J. R. Carson, D. N. McKinstry, S. Wong, J. Med. Chem. 1971, 14 (7), 646-647.
23. H. Bundgaard, N. M. Nielsen, Int. J. Pharm. 1988, 43 (1-2), 101-110.
24. J. Easmon, G. Puerstinger, T. Roth, H. H. Fiebig, M. Jenny, W. Jaeger, G. Heinisch, J. Hofmann, Int. J. Cancer 2001, 94 (1), 89-96.
25. J. Easmon, G. Pürstinger, K. S. Thies, G. Heinisch, J. Hofmann, J. Med. Chem. 2006, 49 (21), 6343-6350.
26. L. J. Hixson, D. S. Alberts, M. Krutzsch, J. Einsphar, K. Brendel, P. H. Gross, N. S. Paranka, M. Baier, S. Emerson, R. Pamukcu, R. W. Burt, Cancer Epidem. Biomar. Prev. 1994, 3, 433-438.
27. H. J. Woerdenbag, T. A. Moskal, N. Pras, T. M. Malingre, J. Nat. Prod. 1993, 56 (6), 849-856.
28. A. K. Claudius, C. S. Kankipati, R. S. Kilari, S. Hassan, K. Guest, S. T. Russell, C. J. Perry, L. A. Stark, I. D. Nicholl, Oncol. Rep. 2014, 32 (4), 1670-1680.
29. V. V. Sahasrabuddhe, M. Z. Gunja, B. I. Graubard, B. Trabert, L. M. Schwartz, Y. Park, A. R. Hollenbeck, N. D. Freedman, K. A. McGlynn, J. Natl. Cancer. Inst. 2012, 104 (23), 1808-1814.
30. M. D. Jacobson, J. F. Burne, M. C. Raff, EMBO J. 1994, 13, 1899-910.
31. S. Nagata, Cell 1997, 88, 355-365.
32. S. Kumar, Cell Death Differ. 2007, 14, 32-43.
33. H. Sano, K. Kawahito, R. L. Wilder, A. Hashiramoto, S. Mukai, K. Asai, S. Kimura, H. Kato, M. Kondo, T. Hla, Cancer Res. 1995, 55, 3785-3789.
34. O. Trott, A. J. Olson, J. Comput. Chem. 2010, 31, 455-461.
35. K. Gupta, B. S. Selinsky, C. J. Kaub, A. K. Katz, P. J. Loll, J. Mol. Biol. 2004, 335, 503-518.
36. a) G. H. Hegazy, H. I. Ali, Bioorg. Med. Chem. 2012, 20, 1259-1270.
37. b) P. Yadav, P. Singh, A. K. Tewari, Bioorg. Med. Chem.Lett. 2014, 24, 2251-2255.
38. c) G. S. Hassan, S. M. Abou-Seria, G. Kamel, M. M. Ali, Eur. J. Med. Chem. 2014, 76, 482-493.
39. d) K. Ozadali, F. Ozkanli, S. Jain, P. P. N. Rao, C. A. Velazquez-Martinez, Bioorg. Med. Chem. 2012, 20, 202912-2922.
40. e) O. Ünsal-Tan, K. Ozadali, K. Piskin, A. Balkan, Eur. J. Med. Chem. 2012, 57, 59-64.
41. f) O. Ünsal-Tan, K. Özden, A. Rauk, A. Balkan, Eur. J. Med. Chem. 2010, 45, 2345-2352.
42. S. Rollas, Ş. G. Küçükgüzel, Open. Drug. Deliv. J. 2008, 2, 77-85.
43. J. Hofmann, G. Heinisch, J. Easmon, G. Pürstinger, H. H. Fiebig, US 7,112,680. 2006.
44. Y. Zhao, J. Hui, D. Wang, L. Zhu, J. H. Fang, X. D. Zhao, Chem. Pharm. Bull. 2010, 58, 1324-1327.
45. B. Gao, H. L. Shi, X. Li, S. P. Qiu, H. Wu, B. B. Zhang, X. J. Wu, Z. T. Wang, Life Sci. 2014, 108, 63-70.
46. Z. Li, Q. Gao, Anim. Cells. Syst. 2013, 17, 147-153.
47. K. C. Duggan, M. J. Walters, J. Musee, J. M. Harp, J. R. Kiefer, J. A. Oates, L. J. Marnett, J. Biol. Chem. 2010, 285, 34950-34959.
48. J. J. P. Stewart, J. Mol. Model. 2007, 13 (12), 1173-1213.
49. Wavefunction Inc., 2014. Spartan 14, Irvine, CA, USA. Available from: http://www.wavefun.com
50. G. M. Morris, R. Huey, W. Lindstrom, M. F. Sanner, R. K. Belew, D. S. Goodsell, A. J. Olson, J. Comp. Chem. 2009, 16, 2785-2791.
51. S. S. Erdem, S. Türkkan, K. Yelekçi, N.-G. Kelekçi, J. Neural Transm. 2013, 120, 859-862.
52. Accelrys Software Inc., 2013. Discovery Studio Modeling Environment, Release 4.0, San Diego.